BACE1 and Alzheimer disease: It was speculated that BACE1 inhibitors may need to be administered in the presymptomatic stages to patients at high-risk of developing AD, and may only need to partially inhibit BACE1 activity for reducing Aβ load slightly over a long period to have a beneficial effect [14,15].